

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

**Hematological changes of Irinotecan ± MSC in nude mice on day 22
after initial treatment of Irinotecan (24h after third dose)**

<u>Treatment</u>	<u>WBC</u>	<u>RBC</u>	<u>HGB</u>	<u>HCT</u>	<u>MCV</u>	<u>MCH</u>	<u>MCHC</u>	<u>PLT</u>
<u>Control</u>	9.4±3.6	8.7±0.9	16.1±1.6	46.1±2.1	53.4±1.0	18.6±0.1	34.5±0.6	1118±415
<u>MSC(0.2)*</u>	10.3±4.5	9.1±0.5	16.8±0.7	49.4±2.4	54.0±1.0	18.4±0.7	34.0±0.7	756±231
<u>Irinotecan(200)**</u>	3.5±0.5	7.8±1.0	13.8±1.9	40.9±4.2	52.8±0.8	17.5±0.3	32.7±0.6	836±201
<u>Irinotecan(200)** +MSC(0.2)*</u>	8.2±3.1	8.5±0.5	15.4±0.7	44.8±1.8	52.8±1.5	18.0±0.5	34.0±0.6	1174±152

Figure 6

Figure 7A




Figure 7B




Figure 8




Figure 9




Figure 10




Figure 11

Hematological changes induced by Oxaliplatin \pm MSC in nude mice on day 5 after Oxaliplatin treatment

Treatment	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLT
Control	2.69 \pm 1.6	8.75 \pm 0.9	14.9 \pm 1.4	46.7 \pm 4.1	53.3 \pm 0.9	17.1 \pm 0.4	32.0 \pm 0.2	972 \pm 166
MSC(0.2)*	3.45 \pm 2.4	8.30 \pm 0.8	14.0 \pm 1.4	44.8 \pm 4.2	54.0 \pm 1.2	16.8 \pm 0.4	31.2 \pm 0.5	1305 \pm 233
Oxaliplatin(15)**	0.90 \pm 0.8	7.49 \pm 0.6	12.7 \pm 0.9	39.5 \pm 3.0	52.8 \pm 0.9	17.0 \pm 0.4	32.3 \pm 0.8	605 \pm 75
MSC(0.2)* + Oxaliplatin(15)**	2.91 \pm 1.6	7.10 \pm 1.1	12.3 \pm 1.9	38.4 \pm 5.7	54.1 \pm 1.3	17.4 \pm 0.1	32.1 \pm 0.8	922 \pm 214

Figure 12

White blood cells and platelets changes induced by Oxaliplatin ± MSC in nude mice

Treatment	<u>White Blood Cells</u>		<u>Neutrophils</u>		<u>Platelets</u>	
	#(1000/CU MM)	% Control	#(1000/CU MM)	% Control	#(1000/CU MM)	% Control
Control	2.69 ± 1.6	100 %	0.75 ± 0.31	100 %	972 ± 166	100 %
MSC(0.2)	3.45 ± 2.4	128 %	0.97 ± 0.30	129 %	1305 ± 233	134 %
Oxaliplatin(15)	0.90 ± 0.8	33 %	0.19 ± 0.10	25 %	605 ± 75	62 %
MSC(0.2) + Oxaliplatin(15)	2.91 ± 1.6	108 %	0.85 ± 0.50	113 %	922 ± 214	95 %

Figure 13

Differential WBC counts (%) in nude mice on day 5 after Oxaliplatin ± MSC treatment

Treatment	Neutrophils	Lymphocytes	Monocytes	Eosinophis	Basophils	LUC
Control	27.9 ± 11.4	52.5 ± 18.8	0.78 ± 0.31	1.2 ± 0.5	2.90 ± 1.3	15.2 ± 19.1
MSC(0.2)	28.2 ± 8.7	64.1 ± 4.9	0.40 ± 0.29	1.1 ± 0.5	0.98 ± 0.4	5.2 ± 6.9
Oxaliplatin (15)	21.4 ± 11.0	65.0 ± 12.8	0.46 ± 0.54	1.4 ± 2.3	1.60 ± 1.3	9.9 ± 9.0
MSC (0.2) + Oxaliplatin (15)	29.2 ± 17.4	48.2 ± 6.1	1.94 ± 1.84	1.1 ± 0.5	2.10 ± 1.7	19.4 ± 17.2